Abelacimab

Thromboembolic disorders are a major cause of morbidity and mortality worldwide. Anticoagulation therapies represent the primary method for the treatment and/or prevention strategies for thromboembolic diseases. Currently available and approved anticoagulant agents, including warfarin and direct oral anticoagulants (DOACs), all interfere with the components of the common coagulation pathway, which play a key role in maintaining hemostasis.